Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...
1dOpinion
Opinion: A wider look at kratom and Connecticut. Synthetic derivatives and natural leaves differ
While not risk-free, natural leaf kratom offers an accessible option, and many users report that it helps them regain control ...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...
Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...
GlobalData on MSN
Neuphoria scraps social anxiety hopeful after Phase III miss
Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes ...
Learn how to reduce belly fat and show six-pack abs in 2026 using the clean diet, lower ab workouts that you can do at home, ...
5don MSN
Women better protected against early neurodegeneration in Parkinson's disease, study reveals
A large international study involving nearly 700 participants reveals that women with a precursor condition to Parkinson's ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Updated clinical data from the Phase 1/2 ABILITY-1 Study evaluating MDNA11, an emerging best-in-class IL-2 therapy, as a monotherapy and in combination with pembrolizumab, will be presented by Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback